Csenge Advisory Group Sells 785 Shares of Merck & Co., Inc. (NYSE:MRK)


Share on StockTwits

Csenge Advisory Group trimmed its holdings in Merck & Co., Inc. (NYSE:MRK) by 4.5% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 16,476 shares of the company’s stock after selling 785 shares during the quarter. Csenge Advisory Group’s holdings in Merck & Co., Inc. were worth $1,257,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Flagship Private Wealth LLC bought a new stake in Merck & Co., Inc. in the 4th quarter worth about $27,000. Financial Avengers Inc. bought a new stake in Merck & Co., Inc. in the 4th quarter worth about $28,000. Joseph P. Lucia & Associates LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $29,000. Curi Capital bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $29,000. Finally, Veritas Investment Partners UK Ltd. bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $30,000. Institutional investors own 72.86% of the company’s stock.

Merck & Co., Inc. stock opened at $75.98 on Tuesday. The stock has a 50-day moving average of $76.83 and a two-hundred day moving average of $78.38. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.00 and a current ratio of 1.30. Merck & Co., Inc. has a one year low of $71.71 and a one year high of $87.80. The stock has a market cap of $192.26 billion, a PE ratio of 16.81, a price-to-earnings-growth ratio of 1.89 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 29th. The company reported $1.40 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.23). Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The business had revenue of $12.08 billion during the quarter, compared to analysts’ expectations of $12.71 billion. During the same quarter last year, the business posted $1.50 earnings per share. The company’s quarterly revenue was up .2% compared to the same quarter last year. As a group, sell-side analysts predict that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.

A number of research firms have issued reports on MRK. Cantor Fitzgerald restated an “overweight” rating on shares of Merck & Co., Inc. in a research note on Friday, February 5th. SVB Leerink cut their price target on Merck & Co., Inc. from $103.00 to $102.00 and set an “outperform” rating for the company in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Merck & Co., Inc. currently has an average rating of “Buy” and a consensus target price of $97.22.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.

See Also: How Do You Calculate Return on Investment (ROI)?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.